{"generic":"Ethinyl Estradiol\/Norgestrel","drugs":["Cryselle","Ethinyl Estradiol\/Norgestrel","Lo\/Ovral","Low-Ogestrel","Ogestrel","Ovral"],"mono":{"0":{"id":"410368-s-0","title":"Generic Names","mono":"Ethinyl Estradiol\/Norgestrel"},"1":{"id":"410368-s-1","title":"Dosing and Indications","sub":{"0":{"id":"410368-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Contraception:<\/b> Lo\/Ovral(R), 1 tablet ORALLY daily for 21 consecutive days per menstrual cycle; tablets are then discontinued for 7 days (three weeks on, one week off)<\/li><li><b>Contraception:<\/b> Lo\/Ovral(R)-28, 1 white tablet ORALLY daily for 21 consecutive days, followed by 1 pink tablet daily for 7 consecutive days; during the first cycle, the patient should begin the first Sun after the onset of menstruation<\/li><li><b>Contraception:<\/b> Ovral(R), 1 tablet ORALLY daily for 21 consecutive days per menstrual cycle; tablets are then discontinued for 7 days (three weeks on, one week off)<\/li><li><b>Contraception:<\/b> Ovral(R)-28, 1 white tablet ORALLY daily for 21 consecutive days, followed by 1 pink tablet daily for 7 consecutive days<\/li><\/ul>"},"1":{"id":"410368-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>use before menarche is not indicated<\/li><li><b>Contraception:<\/b> after menarche, Low-Ogestrel(R), 1 white tablet ORALLY daily for 21 consecutive days, followed by 1 peach tablet daily for 7 consecutive days; during the first cycle, the patient should begin the first Sunday after the onset of menstruation<\/li><\/ul>"},"3":{"id":"410368-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Contraception<br\/>"}}},"2":{"id":"410368-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.<br\/>"},"3":{"id":"410368-s-3","title":"Contraindications\/Warnings","sub":[{"id":"410368-s-3-9","title":"Contraindications","mono":"<ul><li>carcinoma of the breast, known or suspected, or personal history of breast cancer<\/li><li>carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia<\/li><li>cerebral vascular or coronary artery disease, current or history<\/li><li>cholestatic jaundice of pregnancy or jaundice with prior pill use<\/li><li>deep vein thrombophlebitis or thromboembolic disorders, past history<\/li><li>diabetes with vascular involvement<\/li><li>genital bleeding, undiagnosed abnormal<\/li><li>headaches with focal neurological symptoms<\/li><li>hepatic adenomas or carcinomas, or other active liver disease<\/li><li>hypersensitivity to any component of the product<\/li><li>hypertension, uncontrolled<\/li><li>major surgery with prolonged immobilization<\/li><li>pregnancy, known or suspected<\/li><li>thrombogenic rhythm disorders<\/li><li>thrombophilias, hereditary or acquired (Lo\/Ovral-28(R))<\/li><li>thrombophlebitis or thromboembolic disorders<\/li><li>valvular heart disease with thrombogenic complications<\/li><\/ul>"},{"id":"410368-s-3-10","title":"Precautions","mono":"<ul><li>cigarette smoking (15 or more cigarettes per day) and over the age of 35; increased risk of serious cardiovascular side effects including myocardial infarction<\/li><li>abnormal vaginal bleeding; consider nonhormonal causes and take adequate diagnostic measures to rule out malignancy or pregnancy; if pathology ruled out, consider timing or alternate formulation<\/li><li>blood pressure elevation has been reported, particularly in older users and with extended duration of use; women with a history of hypertension, hypertension-related diseases, or renal disease should use an alternative form of birth control or be monitored closely; discontinue if significant elevation in blood pressure occurs<\/li><li>breast cancer; an increased risk has been reported; monitoring recommended<\/li><li>cardiovascular disease risk factors (diabetes, hyperlipidemias, hypertension, obesity); increased risk of morbidity and mortality<\/li><li>cerebrovascular diseases; increased risk of events such as thrombotic and hemorrhagic stroke, particularly in smokers older than 35 years of age who are hypertensive<\/li><li>cervical intraepithelial neoplasia; an increased risk has been reported<\/li><li>contact lens wearers who develop visual changes or changes in lens tolerance should be evaluated by an ophthalmologist<\/li><li>depression, history; monitoring for recurrence recommended; discontinue in serious cases<\/li><li>diabetic and prediabetic women; glucose tolerance may be altered; monitoring recommended<\/li><li>dose-related risk of vascular disease from oral contraceptives; choose the least amount of estrogen and progestogen that is compatible with a low failure rate and the needs to the patient, particularly when initiating use in the treatment-naive<\/li><li>ectopic or intrauterine pregnancy may occur<\/li><li>fluid retention may occur; carefully monitor patients with conditions that may be exacerbated by fluid retention<\/li><li>gallbladder disease requiring surgery has been reported with oral contraceptives<\/li><li>hepatic neoplasia has been reported with oral contraceptive use<\/li><li>HIV infection or sexually transmitted diseases; oral contraceptives offer no protection<\/li><li>hyperlipidemias; changes in triglyceride and lipoprotein levels have been reported; monitoring recommended<\/li><li>liver impairment; oral contraceptives may be poorly metabolized; discontinue if jaundice develops<\/li><li>migraine, history; increased risk of stroke<\/li><li>migraine onset or exacerbation, or development of new pattern recurrent, persistent, or severe headache; discontinue oral contraceptive and evaluate cause<\/li><li>myocardial infarction; increased risk has been reported, primarily in smokers or women with underlying coronary artery disease risk factors<\/li><li>persistence of risk of vascular disease for ever-users of oral contraceptives has been reported<\/li><li>postoperative thromboembolic complications; increased risk reported; discontinue oral contraceptives at least 4 weeks prior to and for 2 weeks after elective surgeries associated with an increased risk of thromboembolism, and during periods of prolonged immobilization<\/li><li>postpartum period, immediate; increased risk of thromboembolism; begin oral contraceptives no earlier than 4 weeks after delivery in women not breastfeeding<\/li><li>retinal thrombosis has been reported; discontinue if there is unexplained partial or complete vision loss, onset of proptosis or diplopia, papilledema, or retinal vascular lesions and immediately undertake appropriate diagnostic and therapeutic measures<\/li><li>thromboembolism and thrombotic disease; increased risk has been reported; underlying conditions that predispose VTE disease may add to risk<\/li><\/ul>"},{"id":"410368-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Ethinyl Estradiol: X (FDA)<\/li><li>Ethinyl Estradiol: B3 (AUS)<\/li><li>Norgestrel: X (FDA)<\/li><li>Norgestrel: B3 (AUS)<\/li><\/ul>"},{"id":"410368-s-3-12","title":"Breast Feeding","mono":"<ul><li>Ethinyl Estradiol: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Ethinyl Estradiol: WHO: Avoid breastfeeding.<\/li><li>Ethinyl Estradiol: Micromedex: Milk effects are possible.<\/li><li>Norgestrel: Micromedex: Infant risk has been demonstrated.<\/li><\/ul>"}]},"4":{"id":"410368-s-4","title":"Drug Interactions","sub":[{"id":"410368-s-4-13","title":"Contraindicated","mono":"<ul><li>Dasabuvir (theoretical)<\/li><li>Ombitasvir (established)<\/li><li>Paritaprevir (established)<\/li><li>Ritonavir (theoretical)<\/li><li>Tranexamic Acid (probable)<\/li><\/ul>"},{"id":"410368-s-4-14","title":"Major","mono":"<ul><li>Anagrelide (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Boceprevir (probable)<\/li><li>Bupropion (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Ceritinib (theoretical)<\/li><li>Clozapine (established)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Felbamate (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Isotretinoin (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Paclitaxel Protein-Bound (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pirfenidone (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Tizanidine (probable)<\/li><li>Ulipristal (established)<\/li><\/ul>"},{"id":"410368-s-4-15","title":"Moderate","mono":"<ul><li>Alprazolam (probable)<\/li><li>Amprenavir (probable)<\/li><li>Aprepitant (probable)<\/li><li>Atazanavir (probable)<\/li><li>Bacampicillin (probable)<\/li><li>Betamethasone (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bosentan (probable)<\/li><li>Clarithromycin (probable)<\/li><li>Colesevelam (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Delavirdine (probable)<\/li><li>Efavirenz (probable)<\/li><li>Eslicarbazepine Acetate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Etravirine (probable)<\/li><li>Fosamprenavir (established)<\/li><li>Fosaprepitant (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Ginseng (probable)<\/li><li>Griseofulvin (established)<\/li><li>Lamotrigine (established)<\/li><li>Licorice (probable)<\/li><li>Modafinil (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><li>Mycophenolic Acid (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Oxcarbazepine (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Prednisolone (established)<\/li><li>Primidone (probable)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>Roflumilast (probable)<\/li><li>Rosuvastatin (probable)<\/li><li>Rufinamide (probable)<\/li><li>Selegiline (probable)<\/li><li>St John's Wort (established)<\/li><li>Telaprevir (established)<\/li><li>Tipranavir (established)<\/li><li>Topiramate (probable)<\/li><li>Troglitazone (probable)<\/li><li>Troleandomycin (established)<\/li><li>Valdecoxib (probable)<\/li><li>Voriconazole (established)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},"5":{"id":"410368-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Weight change finding, Increase or decrease<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain, Bloating symptom, Nausea, Vomiting<\/li><li><b>Musculoskeletal:<\/b>Cramp<\/li><li><b>Neurologic:<\/b>Headache<\/li><li><b>Psychiatric:<\/b>Mood swings<\/li><li><b>Reproductive:<\/b>Amenorrhea, Break-through bleeding, Breast tenderness, Discharge from nipple, Disorder of menstruation, Pain of breast, Scanty vaginal bleeding<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, Thromboembolic disorder<\/li><li><b>Gastrointestinal:<\/b>Disorder of gallbladder<\/li><li><b>Hepatic:<\/b>Neoplasm of liver<\/li><li><b>Neurologic:<\/b>Cerebral hemorrhage<\/li><li><b>Ophthalmic:<\/b>Lesion of eye structure<\/li><li><b>Reproductive:<\/b>Carcinoma of genital organ<\/li><\/ul>"},"6":{"id":"410368-s-6","title":"Drug Name Info","sub":{"0":{"id":"410368-s-6-17","title":"US Trade Names","mono":"<ul><li>Ovral<\/li><li>Lo\/Ovral<\/li><li>Ogestrel<\/li><li>Low-Ogestrel<\/li><li>Cryselle<\/li><\/ul>"},"2":{"id":"410368-s-6-19","title":"Class","mono":"<ul><li>Contraceptive<\/li><li>Estrogen<\/li><li>Progestin<\/li><\/ul>"},"3":{"id":"410368-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"410368-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"410368-s-7","title":"Mechanism Of Action","mono":"Ethinyl estradiol, an estrogen, and norgestrel, a progestogen, is an combination oral contraceptive drug that inhibits ovulation and suppresses gonadotrophin release. It also prevents impregnation by altering the endometrium and the cervical mucus resulting in the prevention of the sperm entry into the uterus.<br\/>"},"9":{"id":"410368-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>take exactly as directed and at intervals not exceeding 24 hours<\/li><li>tablets should be taken at the same time each day<\/li><li>nonhormonal back-up contraception should be used if the patient starts tablets later than the proper day or misses 2 or more active tablets; continue back-up contraception until the patient has taken an active tablet daily for 7 consecutive days<\/li><\/ul>"},"10":{"id":"410368-s-10","title":"Monitoring","mono":"<ul><li>annual history and physical; including blood pressure, cervical cytology and breast exam (in addition to monthly self-exam)<\/li><li>diagnostic measures to rule out malignancy in cases of undiagnosed, persistent\/recurrent abnormal vaginal bleeding<\/li><\/ul>"},"11":{"id":"410368-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norgestrel) 50 MCG-0.5 MG<br\/><\/li><li><b>Ovral-21<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Norgestrel) 50 MCG-0.5 MG<br\/><\/li><\/ul>"},"12":{"id":"410368-s-12","title":"Toxicology","sub":[{"id":"410368-s-12-31","title":"Clinical Effects","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>USES: To suppress the follicle-stimulating hormone luteinizing hormone sequence from the anterior pituitary, resulting in the suppression of ovulation and production of mucus that is less acceptable to spermatozoa. PHARMACOLOGY: An oral contraceptive acts by suppression of gonadotropins. TOXICOLOGY: There are no significant toxic effects from overdose. OVERDOSE: Abdominal pain, nausea, vomiting, headaches, breast tenderness, dysmenorrhea, arterial thromboembolism, hypertension, venous thrombosis, pulmonary embolus, cerebral thrombosis. ADVERSE EFFECTS: Nausea and vomiting with iron containing contraceptives in children, otherwise asymptomatic. <br\/>"},{"id":"410368-s-12-32","title":"Treatment","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: The vast majority of oral contraceptive overdoses require only supportive care. MANAGEMENT OF SEVERE TOXICITY: Severe toxicity is not expected in single substance oral contraceptive ingestion.<\/li><li>Decontamination: There is no need for GI decontamination.<\/li><li>Airway management: Patients with single substance oral contraceptive ingestion will not require airway management.<\/li><li>Antidote: None.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion are not of value.<\/li><li>Monitoring of patient: Concentrations of the hormones in oral contraceptives are not clinically useful. No routine laboratory studies are needed in most patients.<\/li><li>Patient disposition: HOME CRITERIA: Patients with inadvertent ingestions can be managed at home. If oral contraceptives containing iron are ingested, asymptomatic patients ingesting less than 40 mg\/kg elemental iron can be managed at home. OBSERVATION CRITERIA: The following patients should be sent to a healthcare facility for evaluation: Patients with self-harm ingestions; patients ingesting iron-containing oral contraceptives at a dose of more than 40 mg\/kg elemental iron or who have symptoms (nausea, vomiting, or other gastrointestinal complaints). ADMISSION CRITERIA: Patients with pure oral contraceptive overdoses do not need admission. Children with exposure to iron-containing products should follow the iron guidelines for admission. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients for any additional questions.<\/li><\/ul>"},{"id":"410368-s-12-33","title":"Range of Toxicity","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>TOXICITY: A human toxic dose has not been established. Significant toxicity has not been reported after overdose. THERAPEUTIC DOSE: Oral contraceptives are available in various brands, doses, and formulations. <br\/>"}]},"13":{"id":"410368-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to practice safe sex. Drug does not prevent disease transmission.<\/li><li>Discuss potential long-term adverse effects of hormone therapy including myocardial infarction, stroke, thrombophlebitis, dementia, pulmonary embolism, or breast cancer.<\/li><li>This drug may cause chloasma, change in weight, bloating, nausea, stomach cramps, vomiting, migraine, depression, amenorrhea, breakthrough bleeding, breast tenderness or swelling, or nipple discharge.<\/li><li>Tell patient to report persistent\/recurrent abnormal vaginal bleeding.<\/li><li>Patients should report any unexplained partial or complete loss of vision. In addition, patients who wear contact lenses should report visual changes or changes in lens tolerance.<\/li><li>This drug should be taken every day, at the same time each day with not more than 24 h between doses.<\/li><li>Advise patient to use a non-hormonal backup form of contraception for the first 7 days if a Sunday-start regimen is initiated.<\/li><li>Patients should not smoke during therapy, as this increases the risk of serious cardiovascular side effects.<\/li><li>Review with the patient the procedure for handling missed doses. It is very important that the patient follow carefully missed-dose instructions for the particular brand or formulation prescribed in order to prevent pregnancy. In many cases, this will necessitate the use of a back-up method of contraception until the regular schedule has been reestablished.<\/li><li>If patient is still unsure of what to do in the event of a missed dose, patient should use a back-up form of contraception and contact healthcare professional for instructions.<\/li><\/ul>"}}}